$110 Million is the total value of Aquilo Capital Management, LLC's 12 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 7.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARWR | Buy | ARROWHEAD PHARMACEUTICALS IN | $24,410,696 | -20.3% | 908,474 | +5.8% | 22.12% | +30.4% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $19,037,900 | -32.9% | 379,090 | -15.6% | 17.25% | +9.7% |
| RGNX | Sell | REGENXBIO INC | $13,948,599 | -19.8% | 847,424 | -2.6% | 12.64% | +31.1% |
| SLN | SILENCE THERAPEUTICS PLCads | $12,886,128 | +78.5% | 1,312,233 | 0.0% | 11.68% | +191.9% | |
| KYMR | Buy | KYMERA THERAPEUTICS INC | $10,872,844 | -27.4% | 782,219 | +20.1% | 9.85% | +18.7% |
| MRUS | Sell | MERUS N V | $10,141,970 | -50.3% | 430,109 | -44.5% | 9.19% | -18.7% |
| ARVN | Sell | ARVINAS INC | $9,606,965 | -38.0% | 489,153 | -21.6% | 8.71% | +1.4% |
| CCCC | Buy | C4 THERAPEUTICS INC | $3,702,021 | +77.0% | 1,990,334 | +161.7% | 3.36% | +189.5% |
| GMAB | Sell | GENMAB A/Ssponsored ads | $1,839,260 | -72.3% | 52,148 | -70.1% | 1.67% | -54.7% |
| ARGX | Sell | ARGENX SEsponsored adr | $1,826,405 | -71.3% | 3,715 | -77.2% | 1.66% | -53.0% |
| OLMA | Sell | OLEMA PHARMACEUTICALS INC | $1,097,606 | -51.4% | 88,875 | -64.4% | 1.00% | -20.5% |
| PIRS | PIERIS PHARMACEUTICALS INC | $984,351 | +80.1% | 3,303,190 | 0.0% | 0.89% | +194.4% | |
| IWM | Exit | ISHARES RUSSELL 2000 ETF TRput | $0 | – | -150,000 | -100.0% | -15.57% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PIERIS PHARMACEUTICALS INC | 20 | Q3 2023 | 7.1% |
| ARROWHEAD PHARMACEUTICALS INC | 18 | Q3 2023 | 22.1% |
| UNIQURE NV | 18 | Q1 2023 | 10.8% |
| SPERO THERAPEUTICS INC | 16 | Q3 2022 | 15.8% |
| REGENXBIO INC | 16 | Q3 2023 | 12.6% |
| BLUEPRINT MEDICINES CORP | 15 | Q3 2023 | 17.3% |
| ARGENX SE | 15 | Q3 2023 | 3.7% |
| SPDR S&P BIOTECH ETF TR | 14 | Q4 2022 | 52.1% |
| MERUS N V | 14 | Q3 2023 | 13.0% |
| GENMAB A/S | 13 | Q3 2023 | 3.9% |
View Aquilo Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Spero Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Merus N.V. | February 14, 2020 | 814,505 | 2.8% |
| SYNLOGIC, INC.Sold out | February 14, 2020 | 0 | 0.0% |
View Aquilo Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-03-18 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
View Aquilo Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.